ImmunityBio Shares Surge as EU Approves ANKTIVA for Bladder Cancer

The European Commission’s decision to grant marketing authorization for ANKTIVA (nogapendekin alfa inbakicept-pmln) on February 18, 2026, represents a watershed moment for ImmunityBio, effectively doubling the potential market for its flagship oncology product. The approval specifically targets patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. This regulatory win triggered an immediate and sharp appreciation in ImmunityBio’s stock price on the Nasdaq, as investors reacted to the company’s successful navigation of the rigorous European Medicines Agency (EMA) review process. The transition from a domestic U.S. provider to an international commercial entity is a high-stakes evolution for any biotech, and this approval validates ImmunityBio’s global regulatory strategy and its ability to scale operations across the Atlantic.

At the heart of the excitement is ANKTIVA’s status as a first-in-class IL-15 receptor agonist. Unlike traditional immunotherapies that may broadly stimulate the immune system or remove biological brakes—such as checkpoint inhibitors like Merck's Keytruda—ANKTIVA is a superagonist designed to specifically activate the body’s natural killer (NK) cells and CD8+ killer T cells. By mimicking the biological activity of the IL-15 cytokine, it creates a targeted immune response that is particularly effective in the localized environment of the bladder. The clinical data supporting this approval, largely derived from the QUILT-3.032 trial, demonstrated that the combination of ANKTIVA and BCG could achieve durable complete responses in patients who had otherwise run out of options. For many of these patients, the only remaining alternative would have been a radical cystectomy, a life-altering surgery to remove the bladder entirely. The ability to offer a bladder-sparing treatment is a powerful value proposition in the European healthcare landscape, where quality of life and long-term surgical costs are heavily scrutinized.

“

This regulatory win triggered an immediate and sharp appreciation in ImmunityBio’s stock price on the Nasdaq, as investors reacted to the company’s successful navigation of the rigorous European Medicines Agency (EMA) review process.

The strategic implications of this approval extend far beyond the immediate revenue potential of the European market. By securing a foothold in the EU, ImmunityBio establishes a precedent for its IL-15 platform that could streamline future approvals for other indications. The company is currently investigating the superagonist in several other high-value areas, including non-small cell lung cancer (NSCLC) and Lynch syndrome. The proof-of-concept provided by the NMIBC approval in both the U.S. and the EU strengthens the argument that the IL-15 mechanism is a versatile and potent tool in the oncology toolkit. Furthermore, the approval may act as a catalyst for potential partnership discussions with larger pharmaceutical firms looking to bolster their immunotherapy portfolios with a validated, complementary agent that works synergistically with existing standards of care.

However, the path to commercial success in Europe is distinct from the U.S. landscape. ImmunityBio must now engage in country-by-country price negotiations, a process that can be protracted and complex. European health technology assessment (HTA) bodies, such as Germany’s IQWiG or France’s HAS, will scrutinize the cost-effectiveness of ANKTIVA relative to existing standards of care, including Ferring Pharmaceuticals' Adstiladrin. While the high unmet need in the BCG-unresponsive population provides a strong lever for pricing, the company will need to demonstrate not just clinical efficacy, but also the long-term economic benefits of avoiding costly surgeries and hospitalizations associated with bladder removal. The stock market's bullish reaction suggests confidence that the company can navigate these hurdles, but the next 12 to 18 months will be critical for observing the actual pace of European uptake and the impact of regional reimbursement policies.

From a manufacturing perspective, the global rollout of a complex biologic like ANKTIVA requires a robust and scalable supply chain. ImmunityBio has invested heavily in its own manufacturing capabilities, which may give it a margin advantage over competitors who rely on third-party contract development and manufacturing organizations (CDMOs). As the company scales to meet European demand, maintaining the consistency and purity of the IL-15 superagonist will be paramount. Investors should monitor the company’s upcoming quarterly reports for updates on European launch timelines and any potential regional partnerships that could accelerate distribution across the continent. This approval is not just a win for the company’s balance sheet; it is a significant step forward in the global effort to provide more effective, bladder-sparing treatments for cancer patients worldwide.